 | 
 | |
CU-NP is a rationally designed natriuretic peptide that consists of amino acid chains identical to those produced by the human body, specifically the ring structure of C-type Natriuretic Peptide (CNP) and the N- and C-termini of Urodilatin (URO). CU-NP was designed by researchers at Mayo to combine the favorable hemodynamic venodilating effects of CNP generated via NPR-B receptor agonism, with the beneficial renal effects of URO generated via NPR-A receptor agonism. In-vivo studies have shown CU-NP to increase natriuresis, diuresis, and glomerular filtration rate (GFR) in a dose dependent manner; and to decrease cardiac filling pressure, and inhibit the renin-angiotensin system without inducing significant hypotension. CU-NP is currently in preclinical development.
| |
|
